Skip to main content

Press releases | November 7, 2022

Fried Frank acted as counsel to Centerview Partners as financial advisor to Oyster Point Pharma (Oyster Point) in its $295 million acquisition by Viatris Inc. Oyster Point is a commercial-stage biopharmaceutical company focused on pharmaceutical therapies to treat ophthalmic diseases. Viatris is an American global pharmaceutical and healthcare corporation headquartered in Canonsburg, PA. 

The Fried Frank team was led by partner Roy Tannenbaum.


This communication is for general information only. It is not intended, nor should it be relied upon, as legal advice. In some jurisdictions, this may be considered attorney advertising. Please refer to the firm’s data policy page for further information.